Switch theme
Sign up to access all valuation multiples
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
2010
74
Last FY Revenue n/a
LTM EBITDA -$111M
$358M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Mind Medicine has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$111M.
In the most recent fiscal year, Mind Medicine achieved revenue of n/a and an EBITDA of -$106M.
Mind Medicine expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Mind Medicine valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$111M | XXX | -$106M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$116M | XXX | -$104M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$113M | XXX | -$109M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Mind Medicine's stock price is $7.
Mind Medicine has current market cap of $549M, and EV of $358M.
See Mind Medicine trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $358M | $549M | XXX | XXX | XXX | XXX | $-1.50 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Mind Medicine has market cap of $549M and EV of $358M.
Mind Medicine's trades at n/a EV/Revenue multiple, and -3.4x EV/EBITDA.
Equity research analysts estimate Mind Medicine's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Mind Medicine has a P/E ratio of -4.8x.
See valuation multiples for Mind Medicine and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $549M | XXX | $549M | XXX | XXX | XXX |
| EV (current) | $358M | XXX | $358M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -3.2x | XXX | -3.4x | XXX | XXX | XXX |
| EV/EBIT | -3.1x | XXX | -3.4x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -4.8x | XXX | -5.0x | XXX | XXX | XXX |
| EV/FCF | -4.0x | XXX | -4.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMind Medicine's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.4M for the same period.
Mind Medicine's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Mind Medicine's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Mind Medicine and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 13% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Mind Medicine acquired XXX companies to date.
Last acquisition by Mind Medicine was XXXXXXXX, XXXXX XXXXX XXXXXX . Mind Medicine acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Mind Medicine founded? | Mind Medicine was founded in 2010. |
| Where is Mind Medicine headquartered? | Mind Medicine is headquartered in United States of America. |
| How many employees does Mind Medicine have? | As of today, Mind Medicine has 74 employees. |
| Who is the CEO of Mind Medicine? | Mind Medicine's CEO is Mr. Robert B. Barrow. |
| Is Mind Medicine publicy listed? | Yes, Mind Medicine is a public company listed on NAS. |
| What is the stock symbol of Mind Medicine? | Mind Medicine trades under MNMD ticker. |
| When did Mind Medicine go public? | Mind Medicine went public in 2020. |
| Who are competitors of Mind Medicine? | Similar companies to Mind Medicine include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Mind Medicine? | Mind Medicine's current market cap is $549M |
| Is Mind Medicine profitable? | Yes, Mind Medicine is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Mind Medicine? | Mind Medicine's last 12 months EBITDA is -$111M. |
| What is the current EV/EBITDA multiple of Mind Medicine? | Current EBITDA multiple of Mind Medicine is -3.2x. |
| What is the current FCF of Mind Medicine? | Mind Medicine's last 12 months FCF is -$90.0M. |
| What is the current EV/FCF multiple of Mind Medicine? | Current FCF multiple of Mind Medicine is -4.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
